WorldCat Identities

Patel, Priti

Overview
Works: 18 works in 24 publications in 3 languages and 110 library holdings
Genres: Academic theses 
Roles: Author
Publication Timeline
.
Most widely held works about Priti Patel
 
Most widely held works by Priti Patel
After the coalition : a conservative agenda for Britain by Kwasi Kwarteng( Book )

5 editions published in 2011 in English and held by 72 WorldCat member libraries worldwide

In After the Coalition five new Conservative Members of Parliament tackle the challenges of contemporary Britain. They argue that Conservative principles adapted to the modern world are essential for national success. For Britain to prosper in today's global economy, we need a new era of responsibility, for governments as well as individuals. The Conservative Party last won a general election in 1992. The formation of the coalition in 2010 ushered in a politics of compromise for the important task of bringing the deficit under control. At the next election, the Conservative Party may well figh
Behind the wire : an update to Ending secret detentions by Deborah Pearlstein( Book )

2 editions published in 2005 in English and held by 14 WorldCat member libraries worldwide

Reapplying or applying to be a legal aid provider by Alison Hill( Book )

1 edition published in 2011 in English and held by 5 WorldCat member libraries worldwide

Chronopharmaceutical drug delivery of Salbutamol Sulphate : time dependent pulsatile drug delivery system by Priti Patel( Book )

2 editions published in 2012 in German and English and held by 4 WorldCat member libraries worldwide

Osmotic drug delivery of verapamil hydrochloride by Ravi Doshi( )

1 edition published in 2012 in German and held by 2 WorldCat member libraries worldwide

Tackling cervical cancer : improving access to cervical cancer services for women in Southern Africa by Nyasha Chingore-Munazvo( Book )

1 edition published in 2012 in English and held by 1 WorldCat member library worldwide

Protecting rights : litigating cases of HIV testing and confidentiality of status by Kitty Barrett-Grant( Book )

1 edition published in 2012 in English and held by 1 WorldCat member library worldwide

How did we get here and where to now? : the coerced sterilisation of HIV-positive women in Namibia by Priti Patel( )

1 edition published in 2008 in English and held by 1 WorldCat member library worldwide

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Background: Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma. Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimise off-target activity. Methods: In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity. The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants. This trial is registered withClinicalTrials.gov, numberNCT02213926 . Findings: From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years. Patients received a median of two (IQR 1–2) previous therapies. At a median follow-up of 15·2 months, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response. The Kaplan-Meier estimated medians for duration of response, progression-free survival, and overall survival were not reached; the 12-month rates were 72% (95% CI 62–80), 67% (58–75), and 87% (79–92%), respectively. The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]). The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]). There were no cases of atrial fibrillation and one case of grade 3 or worse haemorrhage. The median duration of treatment was 13·8 months. Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]). Interpretation: Acalabrutinib treatment provided a high rate of durable responses and a favourable safety profile in patients with relapsed or refractory mantle cell lymphoma. These findings suggest an important role for acalabrutinib in the treatment of this disease population. Funding: Acerta Pharma, a member of the AstraZeneca Group
Executive compensation by Priti Patel( Book )

1 edition published in 2001 in English and held by 1 WorldCat member library worldwide

Hardware software co-design in reconfigurable socs for centralized key management by Priti Patel( )

1 edition published in 2007 in English and held by 1 WorldCat member library worldwide

A bill to amend the amount of the limit in section 15 of the Commonwealth Development Corporation Act 1999 on the governments financial assistance by Great Britain( Book )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Parallel importing restrictions revisited : why should copyright law grant "films" special protection? by Priti Patel( )

1 edition published in 2003 in English and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.72 (from 0.00 for Executive ... to 0.89 for Acalabruti ...)

Alternative Names
Priti Patel britische Politikerin

Priti Patel British politician

Priti Patel Brits politica

Priti Patel brittiläinen poliitikko

Priti Patel politica

Priti Patel política británica

Priti Patel politicien britannique

pritti patel

Пател, Прити

Пріті Пател

פריטי פאטל פוליטיקאית בריטית

ਪ੍ਰੀਤੀ ਪਟੇਲ

പ്രീതി പട്ടേൽ

プリティ・パテル

布里提·帕特尔

Languages